Eidos Therapeutics Inc EIDX Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-300

Price:

$126.39
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,000

Price:

$125.35
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,934

Price:

$124.72
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,498

Price:

$123.48
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-572

Price:

$122.27
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-696

Price:

$121.11
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,747

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,747

Price:

$125.45
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

1,747

Price:

$7.24
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,500

Price:

--

Filings by filing date

Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-300

Price:

$126.39
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,000

Price:

$125.35
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-4,934

Price:

$124.72
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,498

Price:

$123.48
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-572

Price:

$122.27
Jan 13, 2021 (filed on Jan 15, 2021)

Insider Name:

Sinha Uma

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-696

Price:

$121.11
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,747

Price:

--
Jan 11, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,500

Price:

--
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,747

Price:

$125.45
Jan 12, 2021 (filed on Jan 13, 2021)

Insider Name:

Valle Franco

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

1,747

Price:

$7.24

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	101 Montgomery St Ste 2550 SAN FRANCISCO CA 94104-4158
Tel:	N/A
Website:	eidostx.com
IR:	See website

Key People

Jonathan C. Fox President, Chief Medical Officer	Neil Kumar Chief Executive Officer, Director	Uma Sinha Chief Scientific Officer, Director
Cameron Turtle Chief Business Officer

Business Overview

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Financial Overview

For the nine months ended 30 September 2020, EidosTherapeutics Inc revenues decreased 100% to $127K. Net lossincreased from $18.9M to $81.8M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Research and development - Balan increase of 72%to $54.1M (expense), General and administrative increase of82% to $18.5M (expense).

Employees:	70 as of Sep 30, 2020

Reporting Currency:	U.S. Dollars
Enterprise value:	$4,633M as of Sep 30, 2020
Annual revenue (TTM):	$0.13M as of Sep 30, 2020
EBITDA (TTM):	-$99.55M as of Sep 30, 2020
Net annual income (TTM):	-$100.83M as of Sep 30, 2020
Free cash flow (TTM):	-$85.50M as of Sep 30, 2020
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	38,872,893 as of Dec 8, 2020
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

INK Ultra Money Free

INK Ultra Money Videos

Eidos Therapeutics Inc (OQ:EIDX)